THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Gilead to sell HIV drug in 12 additional countries

Email|Print|Single Page| Text size – +
August 1, 2008

NEW YORK—Biotechnology company Gilead Sciences Inc. said Friday it plans to begin selling its HIV drug Atripla in 12 countries including Russia, Mexico and Australia.

Atripla is a daily HIV treatment that combines two Gilead drugs, Viread and Emtriva, with Bristol-Myers Squibb Co.'s Sustiva.

Merck & Co. distributes the drug in 94 developing countries and Bristol-Myers sells it in Europe, but under the new agreement, Gilead will take the primary role in registering and selling the drug in Argentina, Australia, Chile, Hong Kong, Israel, Mexico, New Zealand, Russia, Taiwan, Thailand, Turkey and Uruguay.

Gilead and Merck plan to make the drug available as soon as possible in those countries, and may add other nations to the agreement. They said the new agreement will make the drug available in a total of 138 countries.

© Copyright 2008 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
  • Email
  • Email
  • Print
  • Print
  • Single page
  • Single page
  • Reprints
  • Reprints
  • Share
  • Share
  • Comment
  • Comment
 
  • Share on DiggShare on Digg
  • Tag with Del.icio.us Save this article
  • powered by Del.icio.us
Your Name Your e-mail address (for return address purposes) E-mail address of recipients (separate multiple addresses with commas) Name and both e-mail fields are required.
Message (optional)
Disclaimer: Boston.com does not share this information or keep it permanently, as it is for the sole purpose of sending this one time e-mail.